Hao Jun, Gao Xiang, Wang Ya-Ping, Liu Qing, Zhu Hai, Zhao Shu-Jun, Qin Qiao-Hong, Meng Jie, Li Lin-Lin, Lin Shao-Chong, Song Zhenzhen, Li Hongyu
Gynecologic Oncology, the Third Affiliated Hospital of Zhengzhou University.
Zhengzhou Key Laboratory of Gynecological Oncology, Zhengzhou, Henan, China.
Anticancer Drugs. 2022 Jun 1;33(5):467-477. doi: 10.1097/CAD.0000000000001280.
Endometrial carcinoma is one of the most common gynecologic malignancies. CXCL17-CXCR8 (GPR35) axis is reported to play an indispensability role in tumors. Our purpose is to screen possible prognostic and immune-related factors in endometrial carcinoma by detecting the mRNA and protein expression of CXCL17 and CXCR8. We use the qRT-PCR method to test the mRNA expression of CXCL17 and CXCR8 in 35 pairs of endometrial carcinoma and adjacent tissue. The protein expression of CXCL17 and CXCR8 in 30 cases of normal proliferative endometrium, 30 cases of endometrial atypical hyperplasia and 50 cases of endometrial carcinoma was detected by tissue microarray immunohistochemistry. There was no significant difference in the positive expression rate between endometrial adenocarcinoma tissue and endometrial atypical hyperplasia tissue (P > 0.05). But significantly better than normal proliferative tissue (P < 0.001). Correlation analysis of CXCR8 and CXCL17 in endometrial carcinoma showed a positive correlation (r = 0.9123, P < 0.0001). For patients with endometrial cancer, the overall survival (OS) of patients with high CXCL17 expression was significantly higher than that low CXCL17 expression (log-rank test, P < 0.0001), whereas CXCR8 had no statistical significance. But the expression of CXCR8 is an independent prognostic factor of OS in endometrial carcinoma patients. Our study showed that CXCL17 and CXCR8 may be involved in the occurrence and development of endometrial cancer. High expression of CXCL17 may be used as a biomarker for predicting survival. Because CXCL17 and CXCL18 are related to lymphocytes and immune regulation, they are expected to become potential targets for immunotherapy.
子宫内膜癌是最常见的妇科恶性肿瘤之一。据报道，CXCL17 - CXCR8（GPR35）轴在肿瘤中发挥着不可或缺的作用。我们的目的是通过检测CXCL17和CXCR8的mRNA及蛋白表达，筛选子宫内膜癌中可能的预后及免疫相关因素。我们采用qRT-PCR方法检测35对子宫内膜癌组织及癌旁组织中CXCL17和CXCR8的mRNA表达。通过组织芯片免疫组化检测30例正常增殖期子宫内膜、30例子宫内膜非典型增生及50例子宫内膜癌中CXCL17和CXCR8的蛋白表达。子宫内膜腺癌组织与子宫内膜非典型增生组织的阳性表达率无显著差异（P＞0.05），但显著优于正常增殖组织（P＜0.001）。子宫内膜癌中CXCR8与CXCL17的相关性分析显示呈正相关（r = 0.9123，P＜0.0001）。对于子宫内膜癌患者，CXCL17高表达患者的总生存期（OS）显著高于CXCL17低表达患者（对数秩检验，P＜0.0001），而CXCR8无统计学意义。但CXCR8的表达是子宫内膜癌患者OS的独立预后因素。我们的研究表明，CXCL17和CXCR8可能参与子宫内膜癌的发生发展。CXCL17高表达可能作为预测生存的生物标志物。由于CXCL17和CXCL18与淋巴细胞及免疫调节相关，它们有望成为免疫治疗的潜在靶点。
Zotero 插件